84 results
PRER14A
BXRXQ
Baudax Bio, Inc.
25 Aug 23
Preliminary revised proxy
4:01pm
contribute revenue and cash flow.
Our near-term goals include:
Leveraging our development experience to progress TI-168, and the research experience … with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Under the goals
DEFA14A
EX-99.1
BXRXQ
Baudax Bio, Inc.
9 Aug 23
Additional proxy soliciting materials
5:28pm
those that could contribute revenue and cash flow.
Our near-term goals include:
Leveraging our development experience to progress TI-168 … . Under the goals and policies agreed to by the FDA under the Prescription Drug User Fee Act (“PDUFA”), the FDA’s goal is to review standard
8-K/A
EX-99.1
BXRXQ
Baudax Bio, Inc.
9 Aug 23
Other Events
5:27pm
those that could contribute revenue and cash flow.
Our near-term goals include:
Leveraging our development experience to progress TI-168 … . Under the goals and policies agreed to by the FDA under the Prescription Drug User Fee Act (“PDUFA”), the FDA’s goal is to review standard
8-K
31ajg ndmap
28 Jun 23
Other Events
4:31pm
8-K
EX-99.1
mttgolapp95fd2
12 May 23
Baudax Bio Reports First Quarter Financial Results and Provides Business Update
8:16am
8-K
EX-99.1
fmc74
10 May 23
Regulation FD Disclosure
8:01am
424B3
2xcz8a3nfleutejkcct
28 Apr 23
Prospectus supplement
4:02pm
8-K
EX-99.2
dcgv9a6o 0ujqq
25 Apr 23
Baudax Bio Announces Positive Top-Line Final Results
9:21am
8-K
EX-99.1
i9td23gne6t
25 Apr 23
Baudax Bio Announces Positive Top-Line Final Results
9:21am
8-K
EX-99.1
ockjt
8 Nov 22
Baudax Bio Reports Third Quarter 2022 Financial Results and Business Highlights
4:16pm
8-K
EX-99.1
rja7cxg ons
23 Aug 22
Regulation FD Disclosure
9:02am
8-K
EX-99.1
l6khtc
11 Aug 22
Baudax Bio Reports Second Quarter 2022 Financial Results and Business Highlights
7:05am
8-K
EX-99.2
59r vp0o5
5 May 22
Baudax Bio Reports First Quarter 2022 Financial Results and Business Highlights
7:00am